|

HCB101 Clinical Trials

3 actively recruiting trials across 1 location

Also known as: SIRPα-Fc fusion protein

Pipeline

Phase 1: 1Phase 1/2: 2

Top Sponsors

  • Taipei Veterans General Hospital, Taiwan1
  • FBD Biologics Limited1
  • Chang Gung Memorial Hospital1

Indications

  • Cancer3
  • Refractory Non-Hodgkin Lymphoma1
  • CRC1
  • HNSCC1
  • Advanced Solid Tumor1

Other2 trials

A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
Phase 1/2
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Phase 1/2

Port Saint Lucie, Florida1 trial

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Hematology-Oncology Associates of the Treasure Coast

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.